Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shortage Notification May Have Legislative Momentum Again After BIO Questions Reimbursement Fix

Executive Summary

Preventing shortages through increased communications with manufacturers could gain the upper hand in part because creating economic incentives may prove too difficult and controversial.


Related Content

GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification
“Critical” Drug List Would Be Created Under Shortages Bill
PDUFA V Action Heats Up On Hill With House Hearings In February
“Comprehensive” Drug Shortage Mitigation Bill Under Development In House
FDA’s Drug Shortage Reg Adds More Manufacturers, Products To Notification List
FDA’s Drug Shortage Prevention Tally: 96 Saves In Six Weeks
Drug Shortage Fixes Migrating Toward Economics
Obama's Drug Shortage Efforts Focus On Personnel, Persuasion
Drug Shortages: FDA Wants Advanced Warning; Practitioners Want Even More
Drug Shortage Legislation Gains Momentum With Bipartisan House Bill





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts